Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase I component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2 IV over 1 hour, Day 4 Bendamustine escalating cohorts IV over 1 hour, Days 1 and 4 1 Cycle = 28 days Phase II component Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11 Doxorubicin 30 mg/m2 IV over 1 hour, Day 4 Bendamustine at MTD IV over 1 hour, Days 1 and 4 Filgrastim (if defined in MTD) 5 µg/kg/day SC, Starting day 6 until neutrophil recovery to ANC \>1000 1 Cycle = 28 days; Patients will continue treatment for a total of up to 8 cycles. ECOG Performance Status: 0-2 Hematopoietic: * Absolute neutrophil count (ANC) ≥ 1.2 x K/mm3 * Platelets ≥ 75 x K/mm3 Hepatic: * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * AST ≤ 2.5 x ULN * ALT ≤ 2.5 x ULN Renal: * Serum creatinine \< 3.0 mg/dL Cardiovascular: * LVEF \>45% corrected by MUGA scan or echocardiogram. * No unstable angina pectoris or recent myocardial infarction (within 6 months)